Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,280,713 | $5,445,572 | $7,159,411 | $6,365,177 |
| % Growth | -3% | -23.9% | 12.5% | – |
| Cost of Goods Sold | $3,524,558 | $4,500,649 | $4,825,010 | $4,332,138 |
| Gross Profit | $1,756,155 | $944,923 | $2,334,401 | $2,033,039 |
| % Margin | 33.3% | 17.4% | 32.6% | 31.9% |
| R&D Expenses | $212,036 | $184,663 | $252,142 | $221,099 |
| G&A Expenses | $145,315 | $144,644 | $146,494 | $142,341 |
| SG&A Expenses | $454,675 | $590,130 | $664,996 | $572,835 |
| Sales & Mktg Exp. | $309,359 | $445,486 | $518,502 | $430,493 |
| Other Operating Expenses | $348,134 | $1,031,041 | -$101,251 | $42,909 |
| Operating Expenses | $1,014,844 | $1,805,834 | $1,211,852 | $1,068,874 |
| Operating Income | $741,311 | -$860,911 | $828,623 | $227,475 |
| % Margin | 14% | -15.8% | 11.6% | 3.6% |
| Other Income/Exp. Net | -$15,082 | -$67,423 | $1,228 | -$5,212 |
| Pre-Tax Income | $726,229 | -$928,334 | $829,851 | $222,263 |
| Tax Expense | $101,311 | -$126,175 | $115,164 | -$11,120 |
| Net Income | $646,742 | -$783,258 | $727,426 | $240,788 |
| % Margin | 12.2% | -14.4% | 10.2% | 3.8% |
| EPS | 0.44 | -0.53 | 0.5 | 0.16 |
| % Growth | 183% | -206% | 212.5% | – |
| EPS Diluted | 0.44 | -0.53 | 0.5 | 0.16 |
| Weighted Avg Shares Out | 1,467,200 | 1,467,296 | 1,467,296 | 1,467,296 |
| Weighted Avg Shares Out Dil | 1,467,200 | 1,467,296 | 1,467,296 | 1,467,296 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44,375 | $24,044 | $54,139 | $54,857 |
| Interest Expense | $141,184 | $223,219 | $235,242 | $201,631 |
| Depreciation & Amortization | $331,051 | $384,667 | $318,199 | $307,380 |
| EBITDA | $1,198,465 | -$320,447 | $1,383,292 | $731,274 |
| % Margin | 22.7% | -5.9% | 19.3% | 11.5% |